Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adecatumumab with or without FOLFOX vs FOLFOX after R0 resection of colorectal liver metastases
2008-004706-14Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of adecatumumab in colorectal cancer (CRC) (3 arms), sponsored by Amgen. Primary endpoint: One-year disease-free survival rate. Started Oct 2008; status: completed.
02
Drugs
adecatumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-004706-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004706-14.